Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.

ABSTRACT:

Background/aims

We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication.

Methods

A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)- based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases.

Results

In total, 350 H. pylo

SUBMITTER: Choi YJ 

PROVIDER: S-EPMC9289827 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature